Over the past two months, people confronting a specific type of bladder cancer have received some optimistic news.
Multiple cancer patients have been treated with ANKTIVA® less than eight weeks after the U.S. FDA approved ImmunityBio Inc.’s approved immunotherapy for Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ.
Bladder Cancer Immunotherapy First Commercial Doses Administered
Hospital Nursing Resources Tied to COVID-19 Survival
Findings for both in-hospital death and 30-day postdischarge mortality